Non-thyroidal illness syndrome and SARS-CoV-2-associated multisystem inflammatory syndrome in children
© 2021. The Author(s)..
PURPOSE: COVID-19 disease may result in a severe multisystem inflammatory syndrome in children (MIS-C), which in turn may alter thyroid function (TF). We assessed TF in MIS-C, evaluating its impact on disease severity.
METHODS: We retrospectively considered children admitted with MIS-C to a single pediatric hospital in Milan (November 2019-January 2021). Non-thyroidal illness syndrome (NTIS) was defined as any abnormality in TF tests (FT3, FT4, TSH) in the presence of critical illness and absence of a pre-existing hormonal abnormality. We devised a disease severity score by combining severity scores for each organ involved. Glucose and lipid profiles were also considered. A principal component analysis (PCA) was performed, to characterize the mutual association patterns between TF and disease severity.
RESULTS: Of 26 (19 M/7F) patients, median age 10.7 (IQR 5.8-13.3) years, 23 (88.4%) presented with NTIS. A low FT3 level was noted in 15/23 (65.3%), while the other subjects had varying combinations of hormone abnormalities (8/23, 34.7%). Mutually correlated variables related to organ damage and inflammation were represented in the first dimension (PC1) of the PCA. FT3, FT4 and total cholesterol were positively correlated and characterized the second axis (PC2). The third axis (PC3) was characterized by the association of triglycerides, TyG index and HDL cholesterol. TF appeared to be related to lipemic and peripheral insulin resistance profiles. A possible association between catabolic components and severity score was also noted.
CONCLUSIONS: A low FT3 level is common among MIS-C. TF may be useful to define the impact of MIS-C on children's health and help delineate long term follow-up management and prognosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
Journal of endocrinological investigation - 45(2022), 1 vom: 26. Jan., Seite 199-208 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Calcaterra, V [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
06LU7C9H1V |
|---|
| Anmerkungen: |
Date Completed 12.01.2022 Date Revised 18.02.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s40618-021-01647-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328575666 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328575666 | ||
| 003 | DE-627 | ||
| 005 | 20231225203227.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40618-021-01647-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1095.xml |
| 035 | |a (DE-627)NLM328575666 | ||
| 035 | |a (NLM)34312809 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Calcaterra, V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Non-thyroidal illness syndrome and SARS-CoV-2-associated multisystem inflammatory syndrome in children |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.01.2022 | ||
| 500 | |a Date Revised 18.02.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a PURPOSE: COVID-19 disease may result in a severe multisystem inflammatory syndrome in children (MIS-C), which in turn may alter thyroid function (TF). We assessed TF in MIS-C, evaluating its impact on disease severity | ||
| 520 | |a METHODS: We retrospectively considered children admitted with MIS-C to a single pediatric hospital in Milan (November 2019-January 2021). Non-thyroidal illness syndrome (NTIS) was defined as any abnormality in TF tests (FT3, FT4, TSH) in the presence of critical illness and absence of a pre-existing hormonal abnormality. We devised a disease severity score by combining severity scores for each organ involved. Glucose and lipid profiles were also considered. A principal component analysis (PCA) was performed, to characterize the mutual association patterns between TF and disease severity | ||
| 520 | |a RESULTS: Of 26 (19 M/7F) patients, median age 10.7 (IQR 5.8-13.3) years, 23 (88.4%) presented with NTIS. A low FT3 level was noted in 15/23 (65.3%), while the other subjects had varying combinations of hormone abnormalities (8/23, 34.7%). Mutually correlated variables related to organ damage and inflammation were represented in the first dimension (PC1) of the PCA. FT3, FT4 and total cholesterol were positively correlated and characterized the second axis (PC2). The third axis (PC3) was characterized by the association of triglycerides, TyG index and HDL cholesterol. TF appeared to be related to lipemic and peripheral insulin resistance profiles. A possible association between catabolic components and severity score was also noted | ||
| 520 | |a CONCLUSIONS: A low FT3 level is common among MIS-C. TF may be useful to define the impact of MIS-C on children's health and help delineate long term follow-up management and prognosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Children | |
| 650 | 4 | |a Multisystem inflammatory syndrome | |
| 650 | 4 | |a Non-thyroidal illness syndrome | |
| 650 | 4 | |a Overall Severity Score | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a Triiodothyronine |2 NLM | |
| 650 | 7 | |a 06LU7C9H1V |2 NLM | |
| 650 | 7 | |a Thyrotropin |2 NLM | |
| 650 | 7 | |a 9002-71-5 |2 NLM | |
| 650 | 7 | |a Thyroxine |2 NLM | |
| 650 | 7 | |a Q51BO43MG4 |2 NLM | |
| 700 | 1 | |a Biganzoli, G |e verfasserin |4 aut | |
| 700 | 1 | |a Dilillo, D |e verfasserin |4 aut | |
| 700 | 1 | |a Mannarino, S |e verfasserin |4 aut | |
| 700 | 1 | |a Fiori, L |e verfasserin |4 aut | |
| 700 | 1 | |a Pelizzo, G |e verfasserin |4 aut | |
| 700 | 1 | |a Zoia, E |e verfasserin |4 aut | |
| 700 | 1 | |a Fabiano, V |e verfasserin |4 aut | |
| 700 | 1 | |a Carlucci, P |e verfasserin |4 aut | |
| 700 | 1 | |a Camporesi, A |e verfasserin |4 aut | |
| 700 | 1 | |a Corti, C |e verfasserin |4 aut | |
| 700 | 1 | |a Mercurio, G |e verfasserin |4 aut | |
| 700 | 1 | |a Izzo, F |e verfasserin |4 aut | |
| 700 | 1 | |a Biganzoli, E |e verfasserin |4 aut | |
| 700 | 1 | |a Zuccotti, G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of endocrinological investigation |d 1980 |g 45(2022), 1 vom: 26. Jan., Seite 199-208 |w (DE-627)NLM000412066 |x 1720-8386 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2022 |g number:1 |g day:26 |g month:01 |g pages:199-208 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40618-021-01647-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2022 |e 1 |b 26 |c 01 |h 199-208 | ||